Efficacy of methotrexate in real-world management of giant cell arteritis

A case-control study

Matthew Koster, Karthik Yeruva, Cynthia Crowson, Francesco Muratore, Cristian Labarca, Kenneth J Warrington

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective. To determine the effect of methotrexate (MTX) on relapse risk and glucocorticoid (GC) use in a large single-institution cohort of patients with giant cell arteritis (GCA). Methods. Patients diagnosed with GCA from 1998 to 2013 with confirmed evidence of temporal artery biopsy and/or radiographic evidence of large vessel vasculitis were identified. Each patient with GCA treated with adjunct MTX (case) was matched to a similar patient with GCA treated only with GC (control). GC requirements and relapse events before and after MTX initiation (or corresponding index date) were compared using rate ratios (RR). Results. Eighty-three cases and 83 controls were identified and compared. No significant differences in age, demographics, laboratory variables, baseline disease characteristics, or mean initial prednisone doses were observed. Median [interquartile range (IQR)] time from GCA diagnosis to MTX initiation in cases was 39 (13-80) weeks and the median (IQR) starting dose was 13.5 (10-15) mg/week. RR comparing relapse rates before and after MTX initiation/index date were significantly reduced in both cases (RR 0.32, 95% CI 0.24-0.41) and controls (RR 0.60, 95% CI 0.43-0.86). The decrease in relapse rate was significantly greater in patients taking MTX than in those taking GC alone (p = 0.004). Rates of GC discontinuation did not differ between groups. Conclusion. In this large single-institution cohort, the addition of MTX to GC decreased the rate of subsequent relapse by nearly 2-fold compared to patients taking GC alone. MTX may be considered as adjunct therapy in patients with GCA to decrease the risk of further relapse events.

Original languageEnglish (US)
Pages (from-to)501-508
Number of pages8
JournalJournal of Rheumatology
Volume46
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Giant Cell Arteritis
Methotrexate
Case-Control Studies
Glucocorticoids
Recurrence
Temporal Arteries
Vasculitis
Prednisone
Demography
Biopsy

Keywords

  • Giant Cell Arteritis
  • Glucocorticoids
  • Methotrexate
  • Relapse
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Efficacy of methotrexate in real-world management of giant cell arteritis : A case-control study. / Koster, Matthew; Yeruva, Karthik; Crowson, Cynthia; Muratore, Francesco; Labarca, Cristian; Warrington, Kenneth J.

In: Journal of Rheumatology, Vol. 46, No. 5, 01.01.2019, p. 501-508.

Research output: Contribution to journalArticle

@article{49f246a2989b4c0788440bc7e8e07f02,
title = "Efficacy of methotrexate in real-world management of giant cell arteritis: A case-control study",
abstract = "Objective. To determine the effect of methotrexate (MTX) on relapse risk and glucocorticoid (GC) use in a large single-institution cohort of patients with giant cell arteritis (GCA). Methods. Patients diagnosed with GCA from 1998 to 2013 with confirmed evidence of temporal artery biopsy and/or radiographic evidence of large vessel vasculitis were identified. Each patient with GCA treated with adjunct MTX (case) was matched to a similar patient with GCA treated only with GC (control). GC requirements and relapse events before and after MTX initiation (or corresponding index date) were compared using rate ratios (RR). Results. Eighty-three cases and 83 controls were identified and compared. No significant differences in age, demographics, laboratory variables, baseline disease characteristics, or mean initial prednisone doses were observed. Median [interquartile range (IQR)] time from GCA diagnosis to MTX initiation in cases was 39 (13-80) weeks and the median (IQR) starting dose was 13.5 (10-15) mg/week. RR comparing relapse rates before and after MTX initiation/index date were significantly reduced in both cases (RR 0.32, 95{\%} CI 0.24-0.41) and controls (RR 0.60, 95{\%} CI 0.43-0.86). The decrease in relapse rate was significantly greater in patients taking MTX than in those taking GC alone (p = 0.004). Rates of GC discontinuation did not differ between groups. Conclusion. In this large single-institution cohort, the addition of MTX to GC decreased the rate of subsequent relapse by nearly 2-fold compared to patients taking GC alone. MTX may be considered as adjunct therapy in patients with GCA to decrease the risk of further relapse events.",
keywords = "Giant Cell Arteritis, Glucocorticoids, Methotrexate, Relapse, Vasculitis",
author = "Matthew Koster and Karthik Yeruva and Cynthia Crowson and Francesco Muratore and Cristian Labarca and Warrington, {Kenneth J}",
year = "2019",
month = "1",
day = "1",
doi = "10.3899/jrheum.180429",
language = "English (US)",
volume = "46",
pages = "501--508",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - Efficacy of methotrexate in real-world management of giant cell arteritis

T2 - A case-control study

AU - Koster, Matthew

AU - Yeruva, Karthik

AU - Crowson, Cynthia

AU - Muratore, Francesco

AU - Labarca, Cristian

AU - Warrington, Kenneth J

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective. To determine the effect of methotrexate (MTX) on relapse risk and glucocorticoid (GC) use in a large single-institution cohort of patients with giant cell arteritis (GCA). Methods. Patients diagnosed with GCA from 1998 to 2013 with confirmed evidence of temporal artery biopsy and/or radiographic evidence of large vessel vasculitis were identified. Each patient with GCA treated with adjunct MTX (case) was matched to a similar patient with GCA treated only with GC (control). GC requirements and relapse events before and after MTX initiation (or corresponding index date) were compared using rate ratios (RR). Results. Eighty-three cases and 83 controls were identified and compared. No significant differences in age, demographics, laboratory variables, baseline disease characteristics, or mean initial prednisone doses were observed. Median [interquartile range (IQR)] time from GCA diagnosis to MTX initiation in cases was 39 (13-80) weeks and the median (IQR) starting dose was 13.5 (10-15) mg/week. RR comparing relapse rates before and after MTX initiation/index date were significantly reduced in both cases (RR 0.32, 95% CI 0.24-0.41) and controls (RR 0.60, 95% CI 0.43-0.86). The decrease in relapse rate was significantly greater in patients taking MTX than in those taking GC alone (p = 0.004). Rates of GC discontinuation did not differ between groups. Conclusion. In this large single-institution cohort, the addition of MTX to GC decreased the rate of subsequent relapse by nearly 2-fold compared to patients taking GC alone. MTX may be considered as adjunct therapy in patients with GCA to decrease the risk of further relapse events.

AB - Objective. To determine the effect of methotrexate (MTX) on relapse risk and glucocorticoid (GC) use in a large single-institution cohort of patients with giant cell arteritis (GCA). Methods. Patients diagnosed with GCA from 1998 to 2013 with confirmed evidence of temporal artery biopsy and/or radiographic evidence of large vessel vasculitis were identified. Each patient with GCA treated with adjunct MTX (case) was matched to a similar patient with GCA treated only with GC (control). GC requirements and relapse events before and after MTX initiation (or corresponding index date) were compared using rate ratios (RR). Results. Eighty-three cases and 83 controls were identified and compared. No significant differences in age, demographics, laboratory variables, baseline disease characteristics, or mean initial prednisone doses were observed. Median [interquartile range (IQR)] time from GCA diagnosis to MTX initiation in cases was 39 (13-80) weeks and the median (IQR) starting dose was 13.5 (10-15) mg/week. RR comparing relapse rates before and after MTX initiation/index date were significantly reduced in both cases (RR 0.32, 95% CI 0.24-0.41) and controls (RR 0.60, 95% CI 0.43-0.86). The decrease in relapse rate was significantly greater in patients taking MTX than in those taking GC alone (p = 0.004). Rates of GC discontinuation did not differ between groups. Conclusion. In this large single-institution cohort, the addition of MTX to GC decreased the rate of subsequent relapse by nearly 2-fold compared to patients taking GC alone. MTX may be considered as adjunct therapy in patients with GCA to decrease the risk of further relapse events.

KW - Giant Cell Arteritis

KW - Glucocorticoids

KW - Methotrexate

KW - Relapse

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85063397878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063397878&partnerID=8YFLogxK

U2 - 10.3899/jrheum.180429

DO - 10.3899/jrheum.180429

M3 - Article

VL - 46

SP - 501

EP - 508

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -